Changes in Body Mass Index with Longer-term Integrase Inhibitor Use: a Longitudinal Analysis of REPRIEVE data.
Emma M KileelCarlos D MalvestuttoJanet LoKathleen V FitchCarl J FichtenbaumJudith A AbergMarkella V ZanniEsteban MartinezNwora Lance OkekePrincy KumarEsau JoaoSara H BaresDaniel BernerMarek SmiejaJhoanna C RoaSara McCallumPamela S DouglasHeather J RibaudoSteven K GrinspoonPublished in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (2023)
Weight gain with longer-term INSTI-based regimens remains unknown. Over 2-years of follow-up in REPRIEVE, INSTI use was associated with weight gain among those on an INSTI entry regimen <2 years [+0.27 (0.22, 0.33) vs. 0.17 (0.12, 0.23) kg/m2/year, p=0.01], but not those on an INSTI regimen >2 years at entry.